Enterprise League logo
SPYRYX Biosciences Logo

SPYRYX Biosciences

Durham, United States (US) · Health and Medical

Do you work at SPYRYX Biosciences?

Claim this profile to manage your company.

Verified by Enterprise League

Data quality

Complete · Accuracy

#respiratory therapeutics

#cystic fibrosis

#pulmonary

#rare and orphan diseases

SPYRYX Biosciences is a Health and Medical company based in Durham, United States (US), founded in 2013, with 10-20 employees. SPYRYX Biosciences's profile is verified on Enterprise League.

Overview

SPYRYX Biosciences is a Durham, North Carolina-based biopharmaceutical company dedicated to developing innovative inhaled therapeutics for severe respiratory diseases, with Cystic Fibrosis (CF) as its initial target.

We focus on addressing the underlying mechanisms of lung disease, particularly the dehydration associated with conditions like CF, by utilizing novel peptides that reduce airway surface density of epithelial sodium channels (ENaC).

Our lead program, SPX-101, is currently in a Phase 2 clinical trial, entitled "Hydration for Optimal Pulmonary Effectiveness" (HOPE-1), evaluating the efficacy of our approach in individuals living with CF. Spyryx Biosciences is committed to advancing understanding of airway hydration and respiratory biology through rigorous scientific research and development.

We are a team of dedicated scientists and clinicians driven by a passion for improving the lives of patients suffering from respiratory illnesses.
Visit Official Website

Most teams do this before shortlisting


Contact Details

info@spyryxbio.com

Durham, United States (US), 801-10 Capitola Drive

Founded

2013

Company Type

Private Limited Company

Employees

10-20

Categories

Biopharma
Life Science
Biotechnology

Keywords

#respiratory therapeutics

#cystic fibrosis

#pulmonary

#rare and orphan diseases

Awards

• 2026 OpenSee all

Services

Default Product Image
SPX-101
Biotechnology

An investigational inhaled peptide designed to reduce airway surface density and enhance mucociliary clearance in patients with Cystic Fibrosis and other respiratory diseases.

N/A

Companies teams usually look at after SPYRYX Biosciences

Comparing a few options usually leads to better decisions






  • Save companies to compare later. Useful when sharing options with your team

This is how your company profile looks to others.